Dr. Calum MacRae to Become Senior Advisor to BioSymetrics
Advocate for healthcare technology innovation joins BioSymetrics in a mission to empower the application of AI within biomedicine.
NEW YORK, Feb. 7, 2019 /PRNewswire/ -- BioSymetrics, an artificial intelligence and machine learning SaaS company, announces Dr. Calum MacRae as Senior Advisor. Dr. MacRae is an innovative pioneer in genetics, biology, and drug discovery. With his deep knowledge and expertise, Dr. MacRae will assist BioSymetrics in the design and application of the company's software for use in drug discovery, precision medicine and health systems.
"The introduction of AI into medicine is challenged by a fundamental defect of information content and standards," said Dr. Calum MacRae. "BioSymetrics is leading the promise that we are entering an era in which precision medicine and AI finally attain real world applications; overcoming a number of AI challenges across a wide spectrum of biomedicine."
Dr. Calum MacRae is the Vice Chair for Scientific Innovation at the Department of Medicine at Brigham and Women's Hospital and Associate Professor of Medicine at Harvard Medical School. He is also the leader of the One Brave Idea™ initiative, a diverse team of scientists, together with the latest technologies and scientific advances, with a mission to find the weapons and strategies to win the fight against coronary heart disease.
"I am excited to have Dr. MacRae as our Senior Advisor," said Gabe Musso, Chief Scientific Officer of BioSymetrics. "His experience and knowledge will allow us to navigate the diverse pharmaceutical ecosystem, enabling us to rapidly innovate and advance our products and services."
About BioSymetrics (www.biosymetrics.com)
BioSymetrics Inc. is based in New York, Boston, and Toronto. Serving health systems, biopharmaceutical, precision medicine, and technology companies, BioSymetrics is empowering healthcare and R&D innovation with leading data science and analytics expertise. The company's Augusta™ software platform is focused on making end-to-end machine learning accessible to scientists and life sciences organizations.
SOURCE BioSymetrics
Share this article